Janis Buchanan

KeifeRx LLC is a clinical-stage biopharmaceutical company that develops novel and optimized tyrosine kinase inhibitors (TKIs) for the treatment of neurodegenerative and immune diseases. KeifeRx is based in McLean, VA, and was founded in 2019 by Charbel Moussa and Fernando Pagan. The company's clinical pipeline is led by Nilotinib BE, an optimized, lower dose formulation of Nilotinib, which is currently in a multicenter phase 3 clinical trial for early Alzheimer's disease. KeifeRx's TKI portfolio includes an optimized oral dose of Bosutinib and Gutinib, which are undergoing clinical trials in Lewy body dementia and optimizing and IND enabling studies, respectively. The company's technologies are designed to treat neurodegenerative diseases and an array of inflammatory diseases where there are significant unmet clinical needs and limited therapeutic options. Chris Hoyt has been the CEO of the company since 2021.